News

Jerusalem, Israel, January 2, 2001 - Dan Suesskind, Chief Financial Officer of Teva Pharmaceuticals Industries Ltd. (NASDAQ:TEVA), responding to statements attributed to Teva in a January 2, 2001 analysts conference call by Biovail Corporation (NASDAQ:BVF), stated: 'While it is generally not our policy to comment on the public announcements of other parties, I would like to correct a negative implication in today's Biovail conference call regarding Teva's sales of Biovail products and Teva's own corporate performance. Teva's internal forecasts regarding its sales of the sustained release gener Read More »

WILL LAUNCH IMMEDIATELY Jerusalem, Israel, February 7, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has awarded final approval for Nifedipine XL 30 mg tablets and Etodolac 400 mg tablets and Teva USA will launch both products immediately.Nifedipine XL is the generic version of Pfizer's drug Procardia XL® for the treatment of hypertension and angina. The approval of the 30mg strength was granted following a Citizen's Petition in which Teva and its partner Biovail had requested that Mylan's 180-day exclusivity positio Read More »

Jerusalem, Israel, February 11, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced it will release its fourth quarter and full-year 2000 financial results on Thursday, February 15, 2001. The Company will host a conference call to be webcast on Thursday, February 15, 2001 at 10:00AM EST to discuss the financial results.To access the live webcast go to Teva's web site at www.tevapharm.com and click on the conference call icon. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. A replay of the webcast will be ava Read More »

Jerusalem, Israel, February 14, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced the conclusion of separate agreements with Aventis Pharmaceuticals Inc. and H. Lundbeck A/S which reposition Teva's global innovative interests including Copaxone® and which will permit Teva to enhance its generic R&D effort. "The result of these two agreements reflects a global strategic initiative for Teva. The strategic alliance with our strong partner, Lundbeck, has been extended to include oral Copaxone in Europe with most of the development costs being borne by Lundbeck. Thi Read More »

Consolidated Statements of IncomeBalance Sheet DataSales for the Quarter October-December 2000Jerusalem, Israel, February 15, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income for the fourth quarter ended December 31, 2000 of $57.9 million or $0.43 per share fully diluted, an increase of 44% and 33% respectively.Net sales for the fourth quarter of 2000 were $518.5 million, an increase of 36% over the comparable quarter of 1999. North America accounted for 64% of these sales, Europe for 20%, Israel for 12%, and Rest of the World, for 4%.For the year ended Decem Read More »

WILL LAUNCH IMMEDIATELY Jerusalem, Israel, April 17, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has awarded final approval for Famotidine 20mg and 40mg tablets, upon expiration of the patent on April 15, 2001. Teva USA will launch the products immediately. Famotidine is the generic equivalent to Merck's drug Pepcid® for the treatment of ulcers, gastroesophageal reflux disease and pathological hypersecretory conditions.The combined U.S. annual brand sales of the 20mg and 40mg strengths were approximately $ 585 mill Read More »

Jerusalem, Israel, April 18, 2001 - Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) today announced it will release its first quarter financial results on Wednesday, May 2nd, 2001. The Company will host a conference call to be webcast on May 2nd, 2001 at 10:00AM EST to discuss the financial results.To access the live webcast go to Teva's web site at www.tevapharm.com and click on the conference call icon. Please login at least 10 minutes prior to the conference call in order to download the applicable audio software. A replay of the webcast will be available within 24 hours at the Company's Read More »

Consolidated Statements of IncomeBalance Sheet DataSales for the Quarter October-December 2000Jerusalem, Israel, May 2, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported net income for the first quarter ended March 31, 2001 of $54.8 million or $0.40 per share fully diluted, an increase over last year of 56% and 43% respectively. Net sales for the first quarter of 2001 were $491 million, an increase of 46% over the comparable quarter of 2000. North America accounted for 59% of total sales, Europe for 24%, Israel for 12%, with sales in the rest of the world, accounting for Read More »

180-Day Market Exclusivity Jerusalem, Israel, May 31, 2001 - Teva Pharmaceutical Industries Ltd.(Nasdaq:TEVA)announced today that the U.S. Food and Drug Administration (FDA)has awarded final approval for Famotidine TabletsUSP,10 mg. This OTC product will be marketed through an alliance with Perrigo Company. Launch is anticipated immediately.Famotidine Tablets 10 mg is the generic version of Merck's Pepcid AC for the treatment and prevention of heartburn. Annual sales of the brand in the U.S. are estimated to be $125 million. Teva will have a 180-day market exclusivity period for this product, Read More »

Jerusalem, Israel, June 3, 2001 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration (FDA) has awarded tentative approval for Fluoxetine 10 mg tablets.Fluoxetine is the generic version of Eli Lilly's antidepressant drug - Prozac®.The U.S. 2000 brand sales of this tablet strength were approximately $ 70 million. This tentative approval is further to the tentative approval that Teva received last year for Fluoxetine 10 mg and 20 mg capsules, which had U.S. 2000 branded sales of approx. $ 2.1 billion. The patent exclusivity will expire in Read More »